COST-UTILITY ANALYSIS OF APREMILAST FOR THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN SPAIN

被引：3
|
作者：
Carrascosa, J. M. [1 ]
Vanaclocha, F. [2 ]
Caloto, T. [3 ]
Echave, M. [4 ]
Oyaguez, I [4 ]
Tencer, T. [5 ]
机构：
[1] Germans Trias & Pujol Univ Hosp, Dept Dermatol, Barcelona, Spain
[2] 12 Octubre Univ Hosp, Dept Dermatol, Madrid, Spain
[3] Celgene Corp, Dept Hlth Econ, Madrid, Spain
[4] Pharmacoecon & Outcomes Res Iberia, Madrid, Spain
[5] Celgene Corp, Warren, NJ USA
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.555
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSS31
引用
收藏
页码：A420 / A420
页数：1
相关论文
共 50 条
  • [41] Economic Evaluation of Dupilumab for Moderate-to-Severe Atopic Dermatitis: A Cost-Utility Analysis
    Zimmermann, Marita
    Rind, David
    Chapman, Rick
    Kumar, Varun
    Kahn, Sonya
    Carlson, Josh
    JOURNAL OF DRUGS IN DERMATOLOGY, 2018, 17 (07) : 750 - 756
  • [42] A Uk Based Cost-Utility Analysis Of Indacaterol Versus Formoterol For The Maintenance Treatment Of Moderate To Severe COPD Patients
    Malcolm, W. A.
    Keyzor, I.
    Radwan, A.
    Asukai, Y.
    Ananthapavan, J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [43] Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain
    Darba, Josep
    Kaskens, Lisette
    Vilela, Francesc Sorio
    Lothgren, Mickael
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2015, 7 : 105 - 117
  • [44] Cost-utility analysis of emicizumab for the treatment of severe hemophilia A patients in Canada
    Yu, Jacky K. K.
    Wong, William W. L.
    Keepanasseril, Arun
    Iorio, Alfonso
    Edginton, Andrea N. N.
    HAEMOPHILIA, 2023, 29 (02) : 488 - 497
  • [45] Cost-utility analysis of prophylaxis versus treatment on demand in severe hemophilia A
    Colombo, Giorgio L.
    Di Matteo, Sergio
    Mancuso, Maria Elisa
    Santagostino, Elena
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2011, 3 : 55 - 61
  • [46] COST-UTILITY ANALYSIS OF CERTOLIZUMAB PEGOL VERSUS ALTERNATIVE TUMOR NECROSIS FACTOR-INHIBITORS, FOR THE TREATMENT OF MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS IN SPAIN
    Villoro, R.
    Hidalgo, A.
    Ferro, B.
    Talavera, P.
    VALUE IN HEALTH, 2011, 14 (07) : A310 - A311
  • [47] A cost-utility analysis of losartan versus atenolol in the treatment of mild to moderate hypertension
    Anis, AH
    Sun, H
    Singh, S
    Woolcott, JC
    Nosyk, B
    VALUE IN HEALTH, 2004, 7 (03) : 323 - 323
  • [48] Assessing the cost-utility of psoriasis therapies
    Weiss, S
    Kimball, A
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 52 (03) : P177 - P177
  • [49] COST PER RESPONDER OF APREMILAST VERSUS INFLIXIMAB BIOSIMILAR, ETANERCEPT, ADALIMUMAB, USTEKINUMAB AND SECUKINUMAB IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS IN SPAIN
    Martinez-Sesmero, J. M.
    Schoendorff, C.
    Caloto, T.
    VALUE IN HEALTH, 2016, 19 (07) : A569 - A569
  • [50] COST-UTILITY ANALYSIS OF CERTOLIZUMAB PEGOL PLUS METHOTREXATE FOR THE TREATMENT OF MODERATE-TO-SEVERE ACTIVE RHEUMATOID ARTHRITIS IN GREECE
    Tzanetakos, C.
    Maniadakis, N.
    Kourlaba, G.
    Tzioufas, A.
    Goules, A.
    Theodoratou, T.
    Christou, P.
    VALUE IN HEALTH, 2014, 17 (07) : A382 - A382
12345